Indications and therapeutic possibilities of albumin dyalisis (MARS);Indicaciones y posibilidades terapéuticas de la diálisis de albúmina (MARS)

Revista Espanola de Enfermedades Digestivas

Volumn 95, Issue 12, 2003, Pages 876-889

  Banares Canizares R ^a   Catalina Rodriguez M V ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN;

BRAIN FUNCTION; CHRONIC LIVER DISEASE; DETOXIFICATION; DIALYSIS MEMBRANE; GRAFT FAILURE; GRAFT REJECTION; HEMODIALYSIS; HEMODYNAMICS; HEMOFILTRATION; HUMAN; INFECTION; KIDNEY FUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER SURGERY; LIVER TRANSPLANTATION; PRURITUS; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

ALBUMINS; EQUIPMENT DESIGN; HUMANS; LIVER FAILURE; MEMBRANES, ARTIFICIAL; RENAL DIALYSIS;

EID: 0347765930     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Kamath PS, Wiesner RH, Malindoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
2. Bishmuth H, Samuel D, Castaing D, Williams R, Pereira SP. Liver transplantation in Europe for patients with acute liver failure. Semin Liver Dis 1996; 16: 415-25.
3. Trotter JF, Wachs M, Everson GT, Kam I. Adult to adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002; 14: 1074-82.
4. Mitzner S, Stange J, Peszynski P, Klammt S. Extracorporeal support of the failing liver. Current Op Crit Care 2002; 8: 171-7.
5. Strain AJ, Neuberger JM. A bioartificial liver- state of the art. Science 2002; 295 (5557): 1005-9.
6. Sundback CA, Vacanti JP. Alternatives to liver transplantation: From hepatocyte transplantation to tissue-engineered organs. Gastroenterology 2000; 118: 438-42.
7. Allen WA, Hassaneim T, Bathia SN. Advances in bioartificial liver devices. Hepatology 2001; 34: 447-55.
8. Tzanakakis ES, Hess DJ, Sielaff TD, HU WS. Extracorporeal tissue enginereed liver-assist devices. Annu Rev Biomed Eng 2000; 2: 607-32.
9. Stange J, Mitzner S, Ramlow W, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993; 17: 809-13.
10. Stange J, Mitzner S, Risler T, Erley CM, Lauchart W, Goehl H, et al. Molecular Adsorbent Recycling System (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artificial Organs 1999; 23 (4): 319-30.
11. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993; 39: M621-5.
12. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs 1996; 19: 677-91.
13. Mitzner S, Stange J, Klammt S, Peszynski P, Schmidt R, Nöldge-Schomburg G. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Neprhol 2001; 12: S75-S82.
14. Seige M, Kreymann B, Jeschke B. Long-term treatment of patients with acute exacerbation of chronic liver failure by albumin dialysis. Transplant Proc 1999; 31: 1371-5.
15. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J of Hepatol 2003; 38: 24-31.
16. Schmidt LE, Svendsen LB, Sorensen VR, Mitzner S, Hansen BA, Larsen FS. The effect of the molecular adsorbent recycling system (MARS) on cerebral perfusion in patients with acute on chronic liver failure and hepatic encephalopathy. Hepatology 2000; 32 (4 pt 2): 612 A.
17. Gaspari R, Pennisi MA, Mignani V, et al. Artificial liver support as a bridge to orthotopic liver transplantation in a case of acute liver dysfunction on nonalcoholic steato-hepatitis (NASH). Z Gastroenterol 2001; 39 (Supl. S2): 15-7.
18. Jalan R, Williams R. Acute on Chronic Liver Failure: Pathophysiological basis of therapeutic options. Blood Purif 2002; 20: 252-61.
19. Mitzner S, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, et al. Improvement of multiple organ functions in hepatorenal syndrome during Albumin Dialysis with the Molecular Adsorbent Recirculating System. Ther Apher 2001; 5 (5): 417-22.
20. Mitzner S, Stange J, Klammt S, Peszynski P, Schmidt R. Albumin dialysis using the molecular recirculating system. Curr Opin Nephr Hyp 2001; 10: 777-83.
21. Stange J, Mitzner S, Klammt S, Loock J, Treichel U, Gerken G, et al. New extracorporeal liver support for chronic liver disease complicated by cholestasis-results of a prospective controlled randomized two center trial. J Hepatology 2001; 34 SI: 45 A 1289.
22. Stange J, Mitzner S, Klammt S, Freytag J, Peszynski P, Loock J, et al. Liver support by extracorporeal blood purification: a clinical observation. Liver Transplantation 2000; 6 (5): 603-13.
23. Mitzner S, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective randomized, controlled clinical trial. Liver Transpl 2000; 6 (3): 277-86.
24. Sorkine P, Abrahan RB, Szold O, Biderman P, Kidron A, Merchav H, et al. Role of molecular adsorbent recycling system (MARS) in the treatment of patients with acute exarcebation of chronic liver failure. Crit Care Med 2001; 29 (7): 1332-6.
25. Schmidt LE, Sorensen VR, Svendsen LB, Larsen FS, Stange J, Hansen BA. Improvement of systemic vascular resistance and arterial pressure in patients with acute on chronic liver failure during treatment with the molecular adsorbent recycling system. Hepatology 2000; 32 (4 pt 2): 401 A.
26. Avilés J, Macia M, Pérez F, Moreno A, Navarro JF, Morales S, et al. Efficacy of MARS in 3 patients with hepatorenal syndrome and hepatic encephalopathy: first experience in Spain. Z Gastroenterol Supl. 2001; 39: 20-1.
27. Oliviero A, Mercurio G, Pilato F, Accurso A, Saturno E, Pennisi MA, et al. Motor cortex excitability in severe liver failure: effects of Molecular Adsorbents Recycling System. Z Gastroenterol 2001; 39 (Supl.): 47.
28. Jalan R, Kapoor D, Steiner C, Williams R. MARS in decompensated alcoholic liver disease with multiorgan failure. Z Gastroenterol 2001; 39 (Supl.): 12.
29. Ullench H, Avenhaus W, Menzel J, Lerch M, Domschke W. Employment of MARS (Molecular Adsorbents Recycling System) for replacement of liver detoxification function up to orthothopic liver transplantation. Z Gastroenterol 2001; 39 (Supl.): 46.
30. Wilmer A, Nevens F, Maes B, Yap P. Molecular Adsorbents Recycling System (MARS) for acute on chronic alcoholic hepatitis: a case report. Z Gastroenterol 2001; 39 (Supl.): 45.
31. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Broelsch C, Klammt S, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury leading to severe hyperbilirubinemia. Hepatology 2002; 36: 949-58.
32. Kapoor D, Williams R, Jalan R. MARS: a new treatment for hepatorenal failure. Gastroenterology 2000; 119: 1799-800.
33. Awad SS, Swaniker F, Magee J, Punch J, Bartlett RH. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis. Surgery 2001; 130: 354-62.
34. Lamesch P, Jost U, Schreiter D, Scheibner L, Beier O, Fangmann J, et al. Molecular Adsorbents Recirculating System in patients with liver failure. Transplant Proc 2001; 33: 3480-2.
35. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001; 7 (8): 709-12.
36. Jalan R, Williams R. Improvement of cerebral perfusion after MARS therapy: Further clues about the patogenesis of hepatic encephalopathy?. Liver Transpl 2001; 7(8): 713-5.
37. Kamath PS. Is there life in MARS? Hepatology 2002; 36: 1017-9.
38. Sen S, Jalan R, Williams R. Extracorporeal albumin dialysis in acute-on-chronic liver failure: will it stand the test of time? Hepatology 2002; 36: 1014-6.
39. Wilkinson SP, Weston MJ, Parsons V, Williams R. Dialysis in the treatment of renal failure in liver disease. Clin Nephrol 1977; 8: 287-92.
40. Pérez GO, Oster JR. A critical review of the role of dialysis in the treatment of liver disease. In: Epstein M, ed. The Kidney in Liver Disease. First Edition. New York: Elsevier, 1978. p. 325-35.
41. Mullen KD. Treatment of hepatorenal syndrome: lessons from the MARS trial. Hepatology 2002; 35 (2): 492-3.
42. Arroyo V, Ginés P, Gerbes A, Dudley FJ, Gentillini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
43. Ginés A, Escorsell A, Ginés P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993; 105: 229-36.
44. Novelli G, Rossi M, Pretagostini R, Poli L, Peritore D, Di Nicuolo A, et al. Use of MARS in the treatment of acute liver failure: preliminary monocentric experience. Transplant Proc 2001; 33 (1-2): 1942-4.
45. Abraham RB, Szold O, Merhav H, Biderman P, Kidron A, Nakache R, et al. Rapid resolution of brain edema and improvement cerebral perfusion pressure following the molecular adsorbent recycling system in acute liver failure patients. Transplant Proc 2001; 33 (6): 2897-9.
46. McIntyre CW, Fluck RJ, Freeman JG, Lambie SH. Use of albumin dialysis in the treatment of hepatic and renal dysfunction due to paracetamol intoxication. Nephrol Dial Transplant 2002; 17: 316-7.
47. Kreymann B, Seige M, Schweigart U, Kopp KF, Classen M. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. Journal of Hepatology 1999; 31: 1080-5.
48. Manz T, Bisse E, Ochs A, Cicco A, Grotz W. MARS for the treatment of fulminant Wilson crisis. Z Gastroenterol 2001; 39 (Supl. 2): 49.
49. Sen S, Felldin M, Steiner C, Larsson B, Gillett GT, Olausson M, et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilson's disease. Liver Transplantation 2002; 8: 962-7.
50. Siewert-Delle A, Henriksson BA, Baeckmann L. Albumin dialysis with the MARS for a patient with acute liver failure due to paracetamol intoxication: a case report. Z Gastroenterol 2001; 39 (Supl.): 48.
51. Sen S, Ratnaraj N, Davies NA, Mookerjee RP, Cooper CE, Patsalos PN, et al. Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS). Epilepsia 2003; 44 (2): 265-7.
52. Barrow L, Tanner MS. Copper distribution among serum proteins in paediatric liver disorders and malignancies. Eur J Clin Invest 1988; 18: 555-60.
53. O'Grady. Paracetamol-induced acute liver failure: prevention and management. J Hepatol 1997; 26: 41-6.
54. Makin A, Wendon J, Williams R. A 7 year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology 1995; 109: 1907-16.
55. Shi Y, He J, Chen S, Zhang L, Yang X, Wang Z, et al. MARS: optimistic therapy method in fulminant hepatic failure secondary to cytotoxic mushroom poisoning - a case report. Liver 2002; 22 (Supl. 2): 78-80.
56. Catalina MV, Nuñez O, Ponferrada A, Menchen L, Matilla A, Clemente G, et al. Toxicidad hepática tras ingesta de setas: curso clínico y nuevas perspectivas de tratamiento. Gastroenterología y Hepatología 2003; 26 (7): 417-20.
57. Broelsch CE, Emond JC, Whitington PF, et al. Application of reduced-size liver transplants as split grafts, auxiliary orthotopics grafts and living related segmental transplants. Am Surg 1990; 214: 368-77.
58. Loock J, Treichel U, Gerken G, Broelsch CE, Phillip Th, Heemann U. Treatment of split liver recipients with poor graft function by albumin dialysis (MARS). Z Gastroenterol 2001; 39 (Supl. S2): 18-9.
59. Kasakoff L, Hommann M, Wagner Th, Konig V, Schmidt K, Scheele J. Application of artificial liver support (MARS) after split-liver transplantation in an infant. Z Gastroenterol 2001; 39 (Supl.): 50.
60. Jost U, Sehreiter D, Scheibner L, Lamesch P, Hauss J. Continous venovenous hemofiltration with extracorporeal albumin dialysis "MARS" in critically ill patients before and after liver transplantation. Z Gastroenterol 2001; 39 (Supl. 2): 43.
61. Delafosse B, Garnier E, Dumortier J, Boillot O. Edouard Herriot experience with the MARS in 5 patients experiencing hepatic failure. Z Gastroenterol 2001; 39 (Supl.): 38.
62. Huster D, Schubert C, Achenbach H, Caca K, Mössner J, Berr F. Successful clinical application of extracorporeal albumin dialysis in a patient with bening recurrent intrahepatic cholestasis (BRIC). Z Gastroenterol 2001; 39 (Supl.): 13-4.
63. Parés A, Cisneros L, Salmerón JM, Caballería L, Mas A, Torras A, et al. Molecular Adsorbent Recirculating System: a new procedure for relieving intractable pruritus in patients with primary biliary cirrhosis. J Hepatol 2001 (Supl.): 155.
64. Notohamiprodjo M, Kizner L, El-Banayosy A, et al. Use of the MARS system in liver failure after Heart surgery (in German). J Anaesth Intensivbehandl 2001; 8: 96-97.
65. Notohamiprodjo M, Banayosy A, Kizner L, Schuller V, Korfer R. One year experience with MARS therapy in patients with multiorgan failure in Cardiac Center Bad Oyenhausen. Z Gastroenterol 2001; 39 (Supl. S2): 51.